Teva Vows Appeal After 4 Copaxone Patents Invalidated

Law360, New York (January 31, 2017, 9:26 PM EST) -- A Delaware federal judge sided Monday with generic-drug makers including Sandoz, Mylan and Pfizer and invalidated four patents for Teva’s multiple sclerosis drug Copaxone they were accused of infringing. 

Teva Pharmaceuticals Industries Ltd. immediately vowed to appeal. 

U.S. District Judge Gregory M. Sleet, who conducted a seven-day bench trial in September, said the four patents were invalid as obvious.

“After having considered the entire record in this case and the applicable law, the court concludes that all asserted claims of the patents-in-suit are invalid as obvious,” Judge Sleet wrote.

The consolidated suits filed by Teva dating back to 2014 named Sandoz Inc.,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS